PANOSTAJA EXPANDS ITS BUSINESS INTO ORAL HEALTH CARE BY

New Post Public Reply Private Reply Replies (0) Message Board
News Desk 2018
PANOSTAJA EXPANDS ITS BUSINESS INTO ORAL HEALTH CARE BY ACQUIRING 75% OF THE SHARES IN MEGAKLINIKKA AND ALSO ADJUSTS ITS RESULT MANAGEMENT

Panostaja Oyj                       Stock Exchange Bulletin February 27, 2015                                 11.00 a.m.

PANOSTAJA EXPANDS ITS BUSINESS INTO ORAL HEALTH CARE BY ACQUIRING 75% OF THE SHARES IN MEGAKLINIKKA AND ALSO ADJUSTS ITS RESULT MANAGEMENT

Panostaja Oyj has today signed an agreement for the purchase of shares in Megaklinikka Oy, which offers oral health care services. The intention is to make the transaction binding on the parties within two weeks. In the transaction, Panostaja will buy a 75% share of the company. As a result of the transaction, Panostaja expands its business operations and establishes within the Group a new business area specializing in oral health care.

Founded in 2010, Megaklinikka Oy is a company providing oral health care services. The company is a dental clinic offering a completely new kind of service concept. Its operations are based on a customer-centered approach in which the customer is offered all dental care services in one visit, with top quality and without having to queue. This customer-centered approach is also supported by Megaklinikka’s efficient IT system including an appointment booking system, the development of which has been invested in since the establishment of the company. The company’s head office is located in Helsinki. In 2014, Megaklinikka had net sales of MEUR 5.5 and it employs about 90 staff.

The value of the company’s entire 100% share capital is some MEUR 2.9, of which Panostaja's share is 75%. The sellers also have the opportunity for an additional purchase price of up to MEUR 1.0, which will be set based on the operating margin for the 2015 and 2016 calendar years.

Megaklinikka’s key personnel will continue as minority shareholders with a 25% stake in the company. Panostaja’s aim is to build Megaklinikka into a company that revolutionizes practices in the sector, and to expand business both in Finland and internationally.

 ”In the oral health care sector, there is a need to provide services that are genuinely more customer-centered than before. Megaklinikka’s service model offers a solution to this. Megaklinikka has rapidly grown into a significant and renowned player in the capital region and has good prospects for growth. We are also convinced about the effectiveness and duplicability of this revolutionary business concept both at home and abroad. It is interesting to get involved in a consumer business with a completely new kind of service model,” says Panostaja CEO Juha Sarsama.

”We are happy to have found a renowned and reliable partner that values the entrepreneurial spirit and with whom we can continue in the active development of the company to the next stage. This is a very important as we expand our operations onto the international market,” says Christoffer Nordström, Managing Director of Megaklinikka.

Panostaja’s result management

Panostaja specifies its result management with regard to net sales. The Group’s net sales in the 2015 financial period are expected to be greater than in 2014 (MEUR 154.8). The Group’s EBIT is expected to be on the same level as in the 2014 financial period (MEUR 10.2).

Previous result management December 12, 2014. The Group’s net sales and EBIT in the 2015 financial period are expected to be at the same level as in the 2014 financial period (net sales MEUR 154.8 and EBIT MEUR 10.2).

Megaklinikka Oy’s net sales and EBIT in the financial periods January 1, 2014−December 31, 2014 and January 1, 2013−December 31, 2013 were as follows (FAS):

(EUR 1,000)

  January 1, 2014-December 31, 2014   January 1, 2013- December 31, 2013  
Net sales   5,533 5,598
EBIT   334 50

The balance sheets in the financial statements on December 31, 2014 and December 31, 2013 were as follows:

(EUR 1,000)

  December 31, 2014   December 31, 2013
Permanent assets   1,315 1,209
Stocks   117 72
Receivables and Liquid assets   633 656
Total 2,065 1,937
Equity (incl. capital loans)   192 16
Liabilities   1,874 1,921
Total   2,065 1,937

Panostaja Oyj

Juha Sarsama CEO

Further information:

CEO Juha Sarsama +358 40 774 2099

Megaklinikka Oy Managing Director Christoffer Nordström +358 40 5251 231

Panostaja is an investment company developing Finnish SMEs in the role of an active majority shareholder. The company aims to be the most sought-after partner for business owners selling their companies as well as for the best managers and investors. Together with its partners, Panostaja increases the Group's shareholder value and creates Finnish success stories. After the Megaklinikka transaction, Panostaja operates in nine business areas, and Panostaja Group employs some 1,200 staff. Panostaja’s shares (PNA1V) are quoted on the Nasdaq Helsinki Stock Exchange. In the 2014 financial period, the Group’s net sales totaled MEUR 154.8. www.panostaja.fi

Scroll down for more posts ▼

Top 10 Most Recent News Articles

TORRAS Cases Balance Protection with Slim Design for 2026

Updated Category News Views 202

Are Slim iPhone Cases Really Protecting Your Investment? Anyone who's dropped a brand-new phone knows the pain of watching your investment smack the concrete. But hey, welcome to 2026, where Consumer365's latest rundown on iPhone protective gear turns the spotlight on TORRAS. These folks grabbed attention with their Q3 Air and Q3 Air Pro cases, crafted for iPhone 18 Pro...

Continue Reading
Sinclair Faces Labor Lawsuit for Break-time Violations

Updated Category News Views 199

Sinclair Television Caught in Labor Law Storm When you think of flaring tempers and boardroom brawls, you typically don't think of your everyday TV station. But right now, Sinclair Television of California, LLC is in the hot seat, accused of playing fast and loose with wage packets—specifically, allegedly denying meal periods and rest breaks that California labor laws...

Continue Reading
Borr Drilling's Rig Sinks, Uncertainty Looms Offshore

Updated Category News Views 166

Unexpected Turn of Events at Sea Now here's a gut-punch nobody saw coming. Borr Drilling Limited (NYSE and OSE: BORR) got hit hard when their Prospector 5 drilling rig went under the waves offshore Gabon. This ain't no desk job dilemma; we're talking about a real-life offshore catastrophe. It all went down on October 24, 2026, when the rig experienced a punch through...

Continue Reading
Clarins Dazzles Austin with Skin Longevity Event

Updated Category News Views 42

Clarins Takes Austin by Storm Under the vast Austin sky, something remarkable unfolded as Clarins transformed the scene with a flashy rooftop affair that screamed innovation and elegance. They weren’t just showing off fancy bottles of beauty potion; they were stirring the pot, merging science with a splash of high-end glitz. This wasn’t just another product pitch—it...

Continue Reading
Johnson & Johnson's JNJ-6143 Shines in Prostate Cancer Study

Updated Category News Views 249

Prostate Cancer's Persistent Challenge No one in the healthcare game needs the reminder: prostate cancer is no walk in the park, especially for those grappling with advanced stages. Now picture this—you're on your sixth treatment, and the cloud is not lifting. It's a battle that never ends, with traditional therapies sometimes barely holding the line. JNJ-6143's New...

Continue Reading
Kelun-Biotech's Sacituzumab Tirumotecan Shows Promise in NSCLC

Updated Category News Views 309

Kelun-Biotech's Recent Breakthrough Grab your coffee, and let's chat about something that might just change the lung cancer treatment game: Kelun-Biotech's sacituzumab tirumotecan, or sac-TMT, showing some serious promise in a Phase III trial. With numbers that could make any investor sit up a little straighter, this study has turned heads at the European Society for...

Continue Reading
Lilly's Olomorasib: New Data Sparks Hope for G12C NSCLC

Updated Category News Views 186

New Data Unveiling Potential Shifts in NSCLC Treatment Man, if there's one thing the oncology world craved, it's progress against KRAS G12C-mutant non-small cell lung cancer (NSCLC). We're talking about a challenge as tough as a two-dollar steak. But hey, Eli Lilly's (NYSE:LLY) putting some serious cards on the table with olomorasib, and folks at the ESMO 2026 Congress...

Continue Reading
BAIC FOTON Eyes African Market with Strategic Moves

Updated Category News Views 84

Revving Up for Africa Alright, gearheads and number-crunchers, strap in. BAIC FOTON is making headlines again, and this time they’re zooming right into Africa—like they're claiming pole position on a circuit that's been ignored by many. They’re calling it a “Drive to Great!” but what does that mean for us investors who aren’t just in it for the entertainment?...

Continue Reading
Wenda Pharma's NHWD-870 HCl Shows Promise in Trial

Updated Category News Views 393

Breaking Through in NUT Carcinoma Treatment Imagine battling an aggressive disease with barely any options left, and then something hopeful shows up in the pipeline. That's the story with Zhejiang Wenda Pharma's NHWD-870 HCl, an oral BET inhibitor making waves at the 2026 ESMO Annual Meeting. Facing off against the nasty beast that is NUT carcinoma, this drug didn't just...

Continue Reading
LexisNexis Debuts AI-Guided Field Clarity at IACP 2026

Updated Category News Views 92

LexisNexis Takes a Serious Step Forward The world of law enforcement reporting just got a shake-up. LexisNexis Coplogic Solutions launched a souped-up version of its Desk Officer Reporting System (DORS) at the IACP 2026 event. They paired DORS with Field Clarity, a newfangled AI-powered assistant that aims to make police reporting slicker and more accurate. You can bet...

Continue Reading

Top 5 Most Recently Viewed Articles

Farmmi Receives Extension to Comply with NASDAQ Requirements

Updated Category News Views 64

Farmmi Secures NASDAQ Compliance Extension Farmmi, Inc. (NASDAQ: FAMI), a supplier of agricultural products, has been granted a 180-day extension by NASDAQ to meet its crucial minimum bid price requirement. This extension allows the company until the spring of 2025 to elevate its ordinary share bid price to at least $1.00 for at least ten consecutive business days. The...

Continue Reading
The Neurotechnology Surge: $57B Market by 2034

Updated Category News Views 16

Neurotechnology: The Rising Giant Elbows on the table, let's chew the fat about neurotechnology. The market, dizzyingly projected to soar past USD 57 billion by 2034, is on an explosive trajectory. Folk wiser than us predict an annual growth rate hanging around 14%. This ain't just whispers in coffee shops; it's cold, hard data from DelveInsight’s Market Insights...

Continue Reading
Reviva Pharmaceuticals' New Phase 3 Study for Schizophrenia Drug

Updated Category News Views 99

Reviva Pharmaceuticals' Regulatory Update Reviva Pharmaceuticals Holdings Inc. (NASDAQ: RVPH) has recently provided an update regarding their journey with brilaroxazine, a novel drug aimed at treating schizophrenia. This news comes after a pre-New Drug Application meeting with the U.S. Food and Drug Administration (FDA). About Brilaroxazine Brilaroxazine is an innovative...

Continue Reading
Lowe's Reports Strong Earnings Amid Strategic Acquisitions

Updated Category News Views 117

Strong Q2 Earnings Surprise Lowe’s Companies Inc (NYSE: LOW) experienced better-than-expected second quarter earnings, bringing a burst of optimism for investors. The home improvement giant saw its stock increase by approximately 2% shortly after announcing its Q2 financial results. Having recorded solid performance through the quarter, Lowe’s exceeded analysts'...

Continue Reading
Invideo and Kling AI Unite for Game-Changing Visuals

Updated Category News Views 153

Invideo and Kling AI Collaborate to Redefine Video Editing Invideo has recently partnered with Kling AI to introduce an exciting tool known as VFX House. This innovative feature empowers creators with studio-level control for their video projects, offering enhanced capabilities for both marketing and editorial work. Unlocking New Possibilities with VFX House The...

Continue Reading